Despite the advent of effective statin therapies, atherosclerosis remains the leading cause of cardiovascular disease in the United States and worldwide. In addition to the well-known role of cholesterol as a major risk factor contributing to cardiovascular disease, evidence from many laboratories points to two other critical contributory factors, namely, dysregulated inflammation and metabolism. The latter two factors are inter- dependent, and metabolically active cells, in response to excess nutrient input, can generate a low-grade, chronic inflammation, referred to as metaflammation. This concept has become increasingly important as an epidemic of obesity in the Western world is driving the incidence of insulin resistance, diabetes, and athero- sclerosis, and consequent morbidity and mortality. The long-term goal of our Program Project is to gain a deep and mechanistic understanding of the genetic events and cellular and physiological processes underlying the connections between inflammation, metabolism, and atherogenesis. A central hypothesis is that macrophages are critically important early responders to metabolic stress, and that they in turn, by paracrine mechanisms, influence the responses of other cells crucial in metaflammation, particularly adipocytes and endothelial cells. The specific objectives of this Program are (i) to understand the molecular basis of interleukin-1 receptor/Toll- like receptor-mediated inflammatory responses in macrophages and EC, and delineate their roles in the initiation and pathogenesis of obesity-associated inflammatory disease (Project 1, Dr. Xiaoxia Li), (ii) to utilize mouse genetic, genomic, and proteomic approaches to identify atherosclerosis modifier genes and genetic modifiers of macrophage foam cell lipid droplet metabolism (Project 2, Dr. Jonathan Smith), and (iii) to determine the noncanonical function of glutamyl-prolyl tRNA synthetase (EPRS) as a critical effector of the mTORC1-S6K1 signaling pathway in adipocytes and macrophages, and its contribution to diet-induced obesity and atherosclerosis (Project 3, Dr. Paul Fox). The Project Leaders are a highly integrated and synergistic group employing distinct but complementary approaches, i.e., cell signaling (Li), mouse genetics/genomics/proteomics (Smith), and biochemistry (Fox). Three scientific Cores - Primary Cell and Mouse Metabolism, Atherosclerosis and Lipoprotein Analysis, and Macromolecular Interaction - and an Administration Core provide multi-project support, expertise, and service in a cost-effective manner, significantly strengthening each of the Projects. We anticipate our collaborative effort will lead to the discovery of novel genes, signaling pathways, and macro-molecular interactions that promote or restrict atherogenesis, and that can be leveraged to reduce disease initiation and progression, and support health and longevity.

Public Health Relevance

Overall Program. Narrative Atherosclerosis is the leading cause of cardiovascular disease in the United States. An epidemic of obesity is driving the incidence of atherosclerosis and diabetes, and consequent morbidity and mortality. It is now clear that excess nutrient input generates chronic inflammation that contributes to atherogenesis. The long-term goal of our Program Project is to gain a deep and mechanistic understanding of the genetic events, and cellular and physiological processes, underlying the connections between inflammation, metabolism and atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL029582-35
Application #
9607613
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Hasan, Ahmed a K
Project Start
1997-07-01
Project End
2020-10-31
Budget Start
2018-11-01
Budget End
2020-10-31
Support Year
35
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Herjan, Tomasz; Hong, Lingzi; Bubenik, Jodi et al. (2018) IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling. Nat Immunol 19:354-365
Robinet, Peggy; Milewicz, Dianna M; Cassis, Lisa A et al. (2018) Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council. Arterioscler Thromb Vasc Biol 38:292-303
Zhang, Cun-Jin; Wang, Chenhui; Jiang, Meiling et al. (2018) Act1 is a negative regulator in T and B cells via direct inhibition of STAT3. Nat Commun 9:2745
Han, Juying; Enyindah-Asonye, Gospel; Lin, Feng et al. (2018) CD6 expression has no effect on atherosclerosis in apolipoprotein E-deficient mice. BMC Res Notes 11:229
Sarvestani, Samaneh K; Signs, Steven A; Lefebvre, Veronique et al. (2018) Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids. Oncotarget 9:28717-28730
Arif, Abul; Yao, Peng; Terenzi, Fulvia et al. (2018) The GAIT translational control system. Wiley Interdiscip Rev RNA 9:
Hai, Qimin; Ritchey, Brian; Robinet, Peggy et al. (2018) Quantitative Trait Locus Mapping of Macrophage Cholesterol Metabolism and CRISPR/Cas9 Editing Implicate an ACAT1 Truncation as a Causal Modifier Variant. Arterioscler Thromb Vasc Biol 38:83-91
Eswarappa, Sandeep M; Potdar, Alka A; Sahoo, Sarthak et al. (2018) Metabolic origin of the fused aminoacyl-tRNA synthetase, glutamyl-prolyl-tRNA synthetase. J Biol Chem 293:19148-19156
Halawani, Dalia; Gogonea, Valentin; DiDonato, Joseph A et al. (2018) Structural control of caspase-generated glutamyl-tRNA synthetase by appended noncatalytic WHEP domains. J Biol Chem 293:8843-8860
Shao, Xinrui; Chen, Siyuan; Yang, Daping et al. (2017) FGF2 cooperates with IL-17 to promote autoimmune inflammation. Sci Rep 7:7024

Showing the most recent 10 out of 276 publications